NCNA - NuCana plc

1.9601
-0.170   -8.668%

Share volume: 57,920
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$2.13
-0.17
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 18%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.83%
1 Month
-11.71%
3 Months
-52.65%
6 Months
-32.18%
1 Year
106.59%
2 Year
-75.67%
Key data
Stock price
$1.96
P/E Ratio 
0.00
DAY RANGE
$1.95 - $2.22
EPS 
-$0.01
52 WEEK RANGE
$0.03 - $7.22
52 WEEK CHANGE
$120.24
MARKET CAP 
9.673 M
YIELD 
N/A
SHARES OUTSTANDING 
2.643 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-15-2025
BETA 
2.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,189
AVERAGE 30 VOLUME 
$34,286
Company detail
CEO: Hugh S. Griffith
Region: US
Website: nucana.com
Employees: 30
IPO year: 2017
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NuCana plc engages in the development of products for the treatment of cancer. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil.

Recent news